GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (OCSE:ALK B) » Definitions » Cyclically Adjusted PS Ratio

Alk-Abello A/S (OCSE:ALK B) Cyclically Adjusted PS Ratio : 8.08 (As of Jun. 09, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello A/S Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Alk-Abello A/S's current share price is kr143.70. Alk-Abello A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr17.78. Alk-Abello A/S's Cyclically Adjusted PS Ratio for today is 8.08.

The historical rank and industry rank for Alk-Abello A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

OCSE:ALK B' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.75   Med: 6.44   Max: 11.89
Current: 8.08

During the past years, Alk-Abello A/S's highest Cyclically Adjusted PS Ratio was 11.89. The lowest was 2.75. And the median was 6.44.

OCSE:ALK B's Cyclically Adjusted PS Ratio is ranked worse than
62.5% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs OCSE:ALK B: 8.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alk-Abello A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was kr6.406. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr17.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alk-Abello A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alk-Abello A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Cyclically Adjusted PS Ratio Chart

Alk-Abello A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.16 9.12 11.72 5.84 5.85

Alk-Abello A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.31 4.41 4.62 5.85 6.98

Competitive Comparison of Alk-Abello A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Alk-Abello A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello A/S's Cyclically Adjusted PS Ratio falls into.



Alk-Abello A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alk-Abello A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=143.70/17.78
=8.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alk-Abello A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.406/118.4000*118.4000
=6.406

Current CPI (Mar. 2024) = 118.4000.

Alk-Abello A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.105 99.700 3.687
201409 2.640 99.700 3.135
201412 3.111 99.400 3.706
201503 3.301 100.200 3.901
201506 2.616 100.300 3.088
201509 3.227 100.200 3.813
201512 3.404 99.800 4.038
201603 4.137 100.200 4.888
201606 3.758 100.600 4.423
201609 3.231 100.200 3.818
201612 3.764 100.300 4.443
201703 4.013 101.200 4.695
201706 3.512 101.200 4.109
201709 3.358 101.800 3.906
201712 3.544 101.300 4.142
201803 3.447 101.700 4.013
201806 3.365 102.300 3.895
201809 2.559 102.400 2.959
201812 3.648 102.100 4.230
201903 3.950 102.900 4.545
201906 3.579 102.900 4.118
201909 3.394 102.900 3.905
201912 3.959 102.900 4.555
202003 4.335 103.300 4.969
202006 3.474 103.200 3.986
202009 3.474 103.500 3.974
202012 4.490 103.400 5.141
202103 4.663 104.300 5.293
202106 4.133 105.000 4.660
202109 4.264 105.800 4.772
202112 4.907 106.600 5.450
202203 4.960 109.900 5.344
202206 4.976 113.600 5.186
202209 4.085 116.400 4.155
202212 5.140 115.900 5.251
202303 5.299 117.300 5.349
202306 5.159 116.400 5.248
202309 4.744 117.400 4.784
202312 5.691 116.700 5.774
202403 6.406 118.400 6.406

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alk-Abello A/S  (OCSE:ALK B) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alk-Abello A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello A/S (OCSE:ALK B) Business Description

Industry
Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello A/S (OCSE:ALK B) Headlines

No Headlines